EP14.05-015 Quantifying Recent Trends in Real-World Treatment Patterns Among Adults Diagnosed with Small Cell Lung Cancer in the U.S. from 2013-2021

Characterizing changes in the small cell lung cancer (SCLC) patient population and SCLC treatment landscape is essential for understanding drivers of outcomes among those patients. Four checkpoint inhibitors (CPIs) were approved for SCLC in 2018 (nivolumab), 2019 (atezolizumab and pembrolizumab), and 2020 (durvalumab), but SCLC was subsequently removed from the nivolumab and pembrolizumab labels in 2020 in 2021, respectively. Durvalumab and atezolizumab are approved for use in the first line (1L) SCLC setting.